Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or inactivating genes. Precisely fixing disease-causing mutations is far more ...

Less than a month after researchers unveiled that a “ticking DNA clock” is behind Huntington’s disease (HD), scientists have ...

This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

In this review, we summarize these technological advancements and discuss about the current challenges in the management of off-target effects for future gene therapy. Cell-free methods reconstitute ...

Researchers developed an epigenetic editing approach to silence the PCSK9 gene, achieving long-term cholesterol reduction ...

Research has uncovered key differences in gene expression linked to inflammation, metabolism and cardioprotection. These findings could help inform the development of targeted therapies for ...

Wayne Danter. [123Genetix] The advantage of AI-enabled gene editing is specificity. Off-target effects are avoided so that when the virtual results are compared to those of CRISPR-Cas9 experiments ...

No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

Stifel analysts adjusted their outlook on CRISPR Therapeutics (NASDAQ:CRSP), currently trading at $43.09 with a market capitalization of $3.7 billion, reducing the price target to $49 from the ...